Millennium Management LLC reduced its stake in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) by 10.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 317,904 shares of the biotechnology company's stock after selling 36,872 shares during the period. Millennium Management LLC owned 0.55% of Kamada worth $1,936,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after buying an additional 1,549 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Kamada during the fourth quarter valued at about $67,000. Aristides Capital LLC raised its holdings in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after buying an additional 6,850 shares in the last quarter. Finally, NewEdge Advisors LLC grew its position in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on KMDA. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Sidoti raised Kamada to a "hold" rating in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price target on shares of Kamada in a research report on Thursday, March 6th. Finally, Benchmark reaffirmed a "buy" rating and issued a $15.00 price target on shares of Kamada in a research report on Thursday, May 15th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $14.67.
View Our Latest Stock Report on Kamada
Kamada Trading Up 1.0%
KMDA stock traded up $0.07 during trading on Friday, reaching $6.85. 74,916 shares of the stock were exchanged, compared to its average volume of 92,024. Kamada Ltd. has a twelve month low of $4.74 and a twelve month high of $9.16. The company has a market capitalization of $393.74 million, a P/E ratio of 24.46, a price-to-earnings-growth ratio of 0.97 and a beta of 0.94. The stock has a 50 day simple moving average of $6.57 and a 200-day simple moving average of $6.68.
Kamada (NASDAQ:KMDA - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, hitting analysts' consensus estimates of $0.07. Kamada had a return on equity of 6.30% and a net margin of 9.92%. The business had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. Equities analysts predict that Kamada Ltd. will post 0.23 EPS for the current year.
About Kamada
(
Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Further Reading
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
